Turning Point (NASDAQ: TPTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.510 | -1.500 | 0.0100 | ||||
REV | 429.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Turning Point (NASDAQ: TPTX) through any online brokerage.
Other companies in Turning Point’s space includes: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sarepta Therapeutics (NASDAQ:SRPT), Karuna Therapeutics (NASDAQ:KRTX), Ionis Pharmaceuticals (NASDAQ:IONS) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Turning Point (NASDAQ: TPTX) was reported by SVB Leerink on Monday, June 13, 2022. The analyst firm set a price target for 76.00 expecting TPTX to rise to within 12 months (a possible 1.18% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Turning Point (NASDAQ: TPTX) is $75.11 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Turning Point.
Turning Point’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Turning Point.
Turning Point is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.